[{"id":"405369f8-6c34-4eaf-86cd-9b205b8bd8af","acronym":"ETCTN 10183","url":"https://clinicaltrials.gov/study/NCT03854474","created_at":"2021-01-18T19:01:24.885Z","updated_at":"2025-02-25T15:18:02.909Z","phase":"Phase 1/2","brief_title":"Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma","source_id_and_acronym":"NCT03854474 - ETCTN 10183","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • PD-1","pipe":" | ","alterations":" EZH2 mutation","tags":["PD-L1 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EZH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • Tazverik (tazemetostat) • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 11/18/2019","start_date":" 11/18/2019","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-12"},{"id":"e098103f-75c1-4aa9-b386-41c1d51fb602","acronym":"MATCH","url":"https://clinicaltrials.gov/study/NCT03155620","created_at":"2021-01-18T15:33:32.929Z","updated_at":"2025-02-25T16:51:52.930Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)","source_id_and_acronym":"NCT03155620 - MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • Vitrakvi (larotrectinib) • Koselugo (selumetinib) • Balversa (erdafitinib) • Retevmo (selpercatinib) • Ensacove (ensartinib) • Zarnestra (tipifarnib) • Tazverik (tazemetostat) • ulixertinib (BVD-523) • samotolisib (LY3023414)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 2316","initiation":"Initiation: 07/31/2017","start_date":" 07/31/2017","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-04"},{"id":"d2101305-ed21-4d8c-a684-029721d03d01","acronym":"NCI-2022-03215","url":"https://clinicaltrials.gov/study/NCT05353439","created_at":"2022-04-29T11:55:38.458Z","updated_at":"2025-02-25T16:26:50.630Z","phase":"Phase 1","brief_title":"Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer","source_id_and_acronym":"NCT05353439 - NCI-2022-03215","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Tazverik (tazemetostat) • topotecan • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Suspended","enrollment":" Enrollment 60","initiation":"Initiation: 07/27/2022","start_date":" 07/27/2022","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2025-01-28"},{"id":"b4088fdb-ec50-47ff-acf6-df6ef4b30a62","acronym":"TAZNI","url":"https://clinicaltrials.gov/study/NCT05407441","created_at":"2022-06-07T22:59:09.709Z","updated_at":"2025-02-25T14:17:01.156Z","phase":"Phase 1/2","brief_title":"Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors","source_id_and_acronym":"NCT05407441 - TAZNI","lead_sponsor":"Susan Chi, MD","biomarkers":" SMARCB1","pipe":" | ","alterations":" SMARCA4 mutation","tags":["SMARCB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SMARCA4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Tazverik (tazemetostat)"],"overall_status":"Recruiting","enrollment":" Enrollment 49","initiation":"Initiation: 08/10/2023","start_date":" 08/10/2023","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 02/01/2029","study_completion_date":" 02/01/2029","last_update_posted":"2024-09-13"},{"id":"ad50b74e-df77-4142-938b-467110fb4a75","acronym":"SYMPHONY-1","url":"https://clinicaltrials.gov/study/NCT04224493","created_at":"2023-06-02T17:05:31.313Z","updated_at":"2024-07-02T16:34:26.311Z","phase":"Phase 3","brief_title":"Study of Tazemetostat Versus Placebo When Given in Combination With Lenalidomide and Rituximab in Participants With Relapsed/Refractory Follicular Lymphoma","source_id_and_acronym":"NCT04224493 - SYMPHONY-1","lead_sponsor":"Epizyme, Inc.","biomarkers":" EZH2","pipe":" | ","alterations":" EZH2 mutation","tags":["EZH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EZH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • lenalidomide • Tazverik (tazemetostat)"],"overall_status":"Recruiting","enrollment":" Enrollment 612","initiation":"Initiation: 06/11/2020","start_date":" 06/11/2020","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2029","study_completion_date":" 03/01/2029","last_update_posted":"2024-06-13"},{"id":"2bbb09d4-a4c2-44c0-86f9-0f0a553fad4d","acronym":"Mandolin","url":"https://clinicaltrials.gov/study/NCT06068881","created_at":"2023-10-05T16:11:20.119Z","updated_at":"2024-07-02T16:34:59.499Z","phase":"Phase 2","brief_title":"A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an \"EZH2 Gain-of-function\" Genetic Mutation","source_id_and_acronym":"NCT06068881 - Mandolin","lead_sponsor":"Epizyme, Inc.","biomarkers":" EZH2","pipe":" | ","alterations":" EZH2 mutation • EZH2 wild-type","tags":["EZH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EZH2 mutation • EZH2 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tazverik (tazemetostat)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 09/02/2024","start_date":" 09/02/2024","primary_txt":" Primary completion: 09/28/2027","primary_completion_date":" 09/28/2027","study_txt":" Completion: 09/28/2027","study_completion_date":" 09/28/2027","last_update_posted":"2024-06-03"},{"id":"d5547275-acd2-4edc-8fac-11affa680d28","acronym":"CELLO-1","url":"https://clinicaltrials.gov/study/NCT04179864","created_at":"2021-01-18T20:22:59.772Z","updated_at":"2024-07-02T16:34:59.510Z","phase":"Phase 1/2","brief_title":"A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer","source_id_and_acronym":"NCT04179864 - CELLO-1","lead_sponsor":"Epizyme, Inc.","biomarkers":" EZH2","pipe":"","alterations":" ","tags":["EZH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • abiraterone acetate • prednisone • Tazverik (tazemetostat)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 102","initiation":"Initiation: 11/18/2019","start_date":" 11/18/2019","primary_txt":" Primary completion: 06/28/2024","primary_completion_date":" 06/28/2024","study_txt":" Completion: 06/28/2024","study_completion_date":" 06/28/2024","last_update_posted":"2024-06-03"},{"id":"25e24245-9e4c-4767-b5e7-b2e9ba8446f8","acronym":"","url":"https://clinicaltrials.gov/study/NCT05983965","created_at":"2023-08-09T14:09:35.762Z","updated_at":"2024-07-02T16:35:05.238Z","phase":"Phase 1","brief_title":"Study of Tazemetostat in Lymphoid Malignancies","source_id_and_acronym":"NCT05983965","lead_sponsor":"University of Alabama at Birmingham","biomarkers":" CD4","pipe":" | ","alterations":" Chr t(11;14) • CCND1 expression","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CCND1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Calquence (acalabrutinib) • Tazverik (tazemetostat)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/01/2024","start_date":" 08/01/2024","primary_txt":" Primary completion: 06/01/2028","primary_completion_date":" 06/01/2028","study_txt":" Completion: 12/01/2029","study_completion_date":" 12/01/2029","last_update_posted":"2024-05-08"},{"id":"a5409d19-a682-484b-8074-dbc0380cdead","acronym":"","url":"https://clinicaltrials.gov/study/NCT02601950","created_at":"2021-01-17T17:38:36.460Z","updated_at":"2024-07-02T16:35:07.229Z","phase":"Phase 2","brief_title":"A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma","source_id_and_acronym":"NCT02601950","lead_sponsor":"Epizyme, Inc.","biomarkers":" CD34 • SS18","pipe":" | ","alterations":" SMARCA4 mutation","tags":["CD34 • SS18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SMARCA4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tazverik (tazemetostat)"],"overall_status":"Completed","enrollment":" Enrollment 267","initiation":"Initiation: 12/22/2015","start_date":" 12/22/2015","primary_txt":" Primary completion: 02/26/2024","primary_completion_date":" 02/26/2024","study_txt":" Completion: 02/26/2024","study_completion_date":" 02/26/2024","last_update_posted":"2024-04-29"},{"id":"e4a4b657-550e-4739-b71c-fff75613dfbe","acronym":"ETCTN 10500","url":"https://clinicaltrials.gov/study/NCT05627245","created_at":"2022-11-25T15:58:14.707Z","updated_at":"2024-07-02T16:35:09.644Z","phase":"Phase 1","brief_title":"Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment","source_id_and_acronym":"NCT05627245 - ETCTN 10500","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EZH2","pipe":" | ","alterations":" RAS wild-type • EZH2 mutation • EZH2 wild-type","tags":["EZH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS wild-type • EZH2 mutation • EZH2 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tazverik (tazemetostat) • Beleodaq (belinostat)"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 03/01/2023","start_date":" 03/01/2023","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2024-04-15"},{"id":"d34b2972-2631-4419-9b42-d2369ac4edd4","acronym":"","url":"https://clinicaltrials.gov/study/NCT04225429","created_at":"2021-01-18T20:34:10.242Z","updated_at":"2024-07-02T16:35:13.248Z","phase":"","brief_title":"Tazemetostat Expanded Access Program for Adults With Epithelioid Sarcoma","source_id_and_acronym":"NCT04225429","lead_sponsor":"Epizyme, Inc.","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tazverik (tazemetostat)"],"overall_status":"No Longer Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2024-03-22"},{"id":"2081d67d-68ba-4944-9cbd-65ba437e972d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05627232","created_at":"2024-01-05T19:19:11.024Z","updated_at":"2024-07-02T16:35:24.396Z","phase":"Phase 1","brief_title":"Palbociclib or Tazemetostat in Combination With CPX-351 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT05627232","lead_sponsor":"Thomas Jefferson University","biomarkers":" CASP3 • ANXA5","pipe":"","alterations":" ","tags":["CASP3 • ANXA5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Vyxeos (cytarabine/daunorubicin liposomal formulation) • Tazverik (tazemetostat)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 08/28/2023","start_date":" 08/28/2023","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2024-01-05"},{"id":"2dd99279-9ac9-4f3f-9024-0d203f7d34e4","acronym":"NRG-GY014","url":"https://clinicaltrials.gov/study/NCT03348631","created_at":"2021-01-18T16:32:10.163Z","updated_at":"2024-07-02T16:35:29.997Z","phase":"Phase 2","brief_title":"Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer","source_id_and_acronym":"NCT03348631 - NRG-GY014","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ARID1A","pipe":" | ","alterations":" MSI-H/dMMR • ARID1A mutation","tags":["ARID1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • ARID1A mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tazverik (tazemetostat)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 05/01/2019","start_date":" 05/01/2019","primary_txt":" Primary completion: 04/14/2023","primary_completion_date":" 04/14/2023","study_txt":" Completion: 09/21/2024","study_completion_date":" 09/21/2024","last_update_posted":"2023-11-08"},{"id":"883c093f-d2f2-4bdb-a6df-2c4fb2930bc9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05890352","created_at":"2023-06-06T14:06:56.792Z","updated_at":"2024-07-02T16:35:34.556Z","phase":"Phase 2","brief_title":"Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment","source_id_and_acronym":"NCT05890352","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" MYC • BCL2 • BCL6 • IRF4 • MME","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["MYC • BCL2 • BCL6 • IRF4 • MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Brukinsa (zanubrutinib) • Tazverik (tazemetostat) • Monjuvi (tafasitamab-cxix)"],"overall_status":"Recruiting","enrollment":" Enrollment 227","initiation":"Initiation: 09/26/2023","start_date":" 09/26/2023","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 01/01/2029","study_completion_date":" 01/01/2029","last_update_posted":"2023-10-05"},{"id":"629d3e43-0e85-4938-b444-ed8c4cd850d5","acronym":"","url":"https://clinicaltrials.gov/study/NCT03028103","created_at":"2021-01-18T14:54:14.823Z","updated_at":"2024-07-02T16:35:44.743Z","phase":"Phase 1","brief_title":"Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients","source_id_and_acronym":"NCT03028103","lead_sponsor":"Epizyme, Inc.","biomarkers":" SLC1A5","pipe":"","alterations":" ","tags":["SLC1A5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Tazverik (tazemetostat) • omeprazole"],"overall_status":"Completed","enrollment":" Enrollment 32","initiation":"Initiation: 03/27/2017","start_date":" 03/27/2017","primary_txt":" Primary completion: 10/31/2019","primary_completion_date":" 10/31/2019","study_txt":" Completion: 11/29/2019","study_completion_date":" 11/29/2019","last_update_posted":"2023-06-26"},{"id":"afa91b8a-c52c-483b-b37d-dc401dac8395","acronym":"","url":"https://clinicaltrials.gov/study/NCT05023655","created_at":"2021-08-26T12:53:15.117Z","updated_at":"2024-07-02T16:35:50.284Z","phase":"Phase 2","brief_title":"Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation","source_id_and_acronym":"NCT05023655","lead_sponsor":"Prisma Health-Upstate","biomarkers":" ARID1A","pipe":" | ","alterations":" ARID1A mutation","tags":["ARID1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ARID1A mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tazverik (tazemetostat)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 01/06/2022","start_date":" 01/06/2022","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2023-04-18"},{"id":"db3fd885-d5b5-42fd-ac3d-e1b4841a432f","acronym":"Epi-RCHOP","url":"https://clinicaltrials.gov/study/NCT02889523","created_at":"2021-01-18T14:10:49.396Z","updated_at":"2024-07-02T16:35:53.084Z","phase":"Phase 1/2","brief_title":"Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy","source_id_and_acronym":"NCT02889523 - Epi-RCHOP","lead_sponsor":"The Lymphoma Academic Research Organisation","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • Tazverik (tazemetostat) • cyclophosphamide intravenous • prednisolone"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 214","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 01/31/2023","primary_completion_date":" 01/31/2023","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2023-03-17"},{"id":"76215dca-1eec-417b-b512-773e2b76f61f","acronym":"CAIRE","url":"https://clinicaltrials.gov/study/NCT04705818","created_at":"2021-01-19T20:51:30.021Z","updated_at":"2025-02-25T14:59:38.130Z","phase":"Phase 2","brief_title":"Combining Epigenetic And Immune Therapy to Beat Cancer.","source_id_and_acronym":"NCT04705818 - CAIRE","lead_sponsor":"Institut Bergonié","biomarkers":" MSI • IFNG","pipe":" | ","alterations":" IFNG expression","tags":["MSI • IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IFNG expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Tazverik (tazemetostat)"],"overall_status":"Recruiting","enrollment":" Enrollment 173","initiation":"Initiation: 07/23/2021","start_date":" 07/23/2021","primary_txt":" Primary completion: 07/01/2023","primary_completion_date":" 07/01/2023","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2023-03-01"},{"id":"ec4f91aa-0ba7-45c0-9101-b6c7390334c5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02601937","created_at":"2021-01-17T17:40:42.252Z","updated_at":"2024-07-02T16:36:19.156Z","phase":"Phase 1","brief_title":"A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma","source_id_and_acronym":"NCT02601937","lead_sponsor":"Epizyme, Inc.","biomarkers":" SS18","pipe":" | ","alterations":" SMARCA4 mutation","tags":["SS18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SMARCA4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tazverik (tazemetostat)"],"overall_status":"Completed","enrollment":" Enrollment 109","initiation":"Initiation: 01/07/2016","start_date":" 01/07/2016","primary_txt":" Primary completion: 10/22/2021","primary_completion_date":" 10/22/2021","study_txt":" Completion: 10/22/2021","study_completion_date":" 10/22/2021","last_update_posted":"2021-12-27"},{"id":"71f7d7d5-8dbb-4ee0-9fc8-5c916cce0f90","acronym":"","url":"https://clinicaltrials.gov/study/NCT02860286","created_at":"2021-01-17T17:30:41.405Z","updated_at":"2024-07-02T16:36:32.130Z","phase":"Phase 2","brief_title":"Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma","source_id_and_acronym":"NCT02860286","lead_sponsor":"Epizyme, Inc.","biomarkers":" BAP1","pipe":" | ","alterations":" BAP1 mutation","tags":["BAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BAP1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tazverik (tazemetostat)"],"overall_status":"Completed","enrollment":" Enrollment 74","initiation":"Initiation: 07/01/2016","start_date":" 07/01/2016","primary_txt":" Primary completion: 06/01/2018","primary_completion_date":" 06/01/2018","study_txt":" Completion: 05/01/2019","study_completion_date":" 05/01/2019","last_update_posted":"2021-04-09"},{"id":"84bb3080-7a42-4ff5-b68c-cf063df06457","acronym":"","url":"https://clinicaltrials.gov/study/NCT02220842","created_at":"2021-01-18T10:24:30.338Z","updated_at":"2024-07-02T16:36:50.895Z","phase":"Phase 1","brief_title":"A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma","source_id_and_acronym":"NCT02220842","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CD20 • IL2","pipe":" | ","alterations":" CD20 positive","tags":["CD20 • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Gazyva (obinutuzumab) • Tazverik (tazemetostat)"],"overall_status":"Completed","enrollment":" Enrollment 96","initiation":"Initiation: 12/18/2014","start_date":" 12/18/2014","primary_txt":" Primary completion: 01/21/2020","primary_completion_date":" 01/21/2020","study_txt":" Completion: 01/21/2020","study_completion_date":" 01/21/2020","last_update_posted":"2020-01-27"}]